The H-ECCO Committee is saying goodbye to Monika Tripathi and would like to thank her for all her work on behalf of the Committee in recent years.

At the same time, as chairman of the Committee, I am very happy to welcome our new member, Aart Mookhoek. Aart currently works as a pathologist at the Institute of Pathology, University of Bern, Switzerland. He is, however, Dutch originally, and developed his passion for gastrointestinal pathology during a residency and subsequent fellowship at the University of Amsterdam, the Netherlands. Aart and I trained together on histological scoring systems for disease activity in Ulcerative Colitis and Crohn’s Disease, and we participated in a research project on this topic.

Gert De Hertogh © ECCO

Contrary to everyone’s ardent expectations and hopes, this year’s ECCO Congress was once again held virtually. While the experiences from 2021 had taught the H-ECCO Committee how to prepare for this and what to expect, we were so happy to be supported again by an excellent ECCO Office team.

Ann Driessen © ECCO

Inflammatory Bowel Disease is a longstanding recurrent inflammatory disorder that is most prevalent in Western countries but is increasing in Asiatic countries. The worldwide increase in the incidence of IBD, comprising Crohn’s Disease, Ulcerative Colitis and IBD unclassified, is having a significant impact on health care systems. Achievement of an optimal quality of care of IBD requires a multidisciplinary approach by different clinical disciplines, including pathology. Histopathology plays an essential role in the diagnosis and management of IBD. The pathologist excludes or confirms and subtypes IBD, assesses its activity and response to treatment and diagnoses preneoplastic lesions on endoscopic biopsies. Suboptimal sampling during endoscopy or insufficient clinical information, however, hampers the pathologist in making a diagnosis [1]. The main histological features of IBD are disturbance of the architecture and basal plasmacytosis, though a wide variety of disorders resemble IBD not only clinically and endoscopically but also histologically. Distinction between IBD and these mimics is essential as misdiagnosis results in delayed and incorrect management. Their differentiation is, however, not always straightforward and, in addition to a standard clinical examination, requires serology, imaging, endoscopy, histology and other investigations [2].

Gert De Hertogh © ECCO

The past 2 years, 2020 and 2021, have been challenging for everybody, but with the help of the ever-enthusiastic ECCO Organisation and their co-workers, the H-ECCO Committee was able to organise a well-attended masterclass at the recent virtual congress in July.

We divided the masterclass into four sessions: Basics of IBD, Scoring Schemes and Standards, Neoplasia and New Concepts in IBD.

Pamela Baldin © ECCO

Paediatric-onset Inflammatory Bowel Diseases (IBDs) represent about 25%–30% of all IBDs. As in adult patients, cases are classified as Ulcerative Colitis (UC) or Crohn’s Disease (CD). In addition, a third diagnostic category, unclassified-IBD (U-IBD), can be used when a definite differential diagnosis between UC and CD is not possible.

Paediatric-onset IBDs, by definition, are those IBDs which are diagnosed in children and adolescents under the age of 17 years. They are further categorised as very early onset IBD (VEO-IBD) when the disease is diagnosed before 6 years of age, infantile IBD when the diagnosis is made before 2 years of age and neonatal-onset IBD when the patient is 28 days old or less. 

Francesca Rosini  © ECCO

The histological diagnosis of Inflammatory Bowel Disease (IBD) is not an easy task for a pathologist. In the modern era, personal pathology experience alone is insufficient to make a diagnosis of IBD. The information that a pathologist must know in order to evaluate IBD samples appropriately and to make a diagnosis is diverse, and for the most part should be provided by the gastroenterologists, surgeons or clinicians responsible for the care of patients. Even the most experienced pathologist cannot report a case without knowing the clinical background of the patient. Obviously, this should be the standard for all samples, not only for IBD.

Ann Driessen © ECCO

Pamela Baldin © ECCO

The animal model is a useful tool to unravel different pathogenetic mechanisms, to detect biomarkers for monitoring and to test the efficacy and safety of drugs in the preclinical phase. In Inflammatory Bowel Disease (IBD) research, the mouse is the most widely used animal model. Animal models are classified into four categories, namely chemical models, cell transfer models, genetically engineered models, and congenic models. Based on the mechanism of the animal model, different aspects of the pathogenesis of intestinal inflammation in IBD are examined, such as epithelial integrity and wound healing, and innate and adaptive immunity [1].

Gert De Hertogh  © ECCO

As the new chair of the H-ECCO Committee, it is my pleasure to introduce our two newly elected members for 2020, Ann Driessen and Pamela Baldin, who are both Belgian pathologists. Thus, the current members of the H-ECCO Committee are: Monika Tripathi (Addenbrooke’s Hospital, Cambridge, UK), Francesca Rosini (Imperial College Healthcare NHS Trust, London, UK), Ann Driessen, Pamela Baldin, and myself, Gert De Hertogh (University Hospitals KULeuven, Belgium).

Roger Feakins © ECCO

The Histopathology Committee of ECCO (H-ECCO) is now more than 5 years old, having started as a new working group. It is an enthusiastic group that supports various activities and interacts well with other ECCO Committees. The most identifiable and consistent activity is the H-ECCO IBD Masterclass, a successful event attracting more than 70 delegates annually from Europe and further afield.

Francesca Rosini © ECCO

Crohn’s Disease (CD) and Ulcerative Colitis (UC) are considered multisystemic diseases. They affect the gastrointestinal tract but can also involve other systems and organs. Almost 50% of patients with Inflammatory Bowel Diseases (IBDs) experience at least one extraintestinal manifestation (EIM). The principal organs and structures affected by EIMs are, amongst others, joints and bones, eyes, liver and the hepatobiliary system and skin [1].